Skip to Content
You are currently on the new version of our website. Access the old version .
HealthcareHealthcare
  • Article
  • Open Access

16 November 2026

11 Pages

Frequency of Isolated IgG-Class tTG/EMA Positivity and Histopathological Findings Potentially Compatible with Celiac Disease in Patients Aged 60 Years and Older Evaluated in Routine Clinical Practice: A Single-Center Retrospective Study in Giresun, Türkiye

,
and
Department of Internal Medicine, Division of Gastroenterology, Faculty of Medicine, Giresun University, 28200 Giresun, Türkiye
*
Author to whom correspondence should be addressed.
Healthcare2026, 14(22), 3926;https://doi.org/10.3390/healthcare14223926 
(registering DOI)

Highlights

What are the main findings?
  • Isolated IgG-class tTG/EMA positivity was detected in 0.9% of serologically evaluated older adults; no patients showed IgA-class tTG or EMA positivity.
  • Histopathological findings potentially compatible with CD were observed in 1.8% of patients undergoing duodenal biopsy, most commonly nonspecific Marsh type 1 changes.
What are the implications of the main findings?
  • Celiac disease should remain in the differential diagnosis of adults aged 60 years and older.
  • Serological and histopathological findings should be interpreted cautiously and in an integrated clinical context.

Abstract

Background/Objectives: Celiac disease (CD) is commonly diagnosed at younger ages but may also occur in older adults, in whom atypical or nonspecific presentations can delay recognition. This study aimed to evaluate the frequency of isolated IgG-class tTG/EMA positivity and histopathological findings potentially compatible with CD in individuals aged 60 years and older and to describe the available demographic and laboratory characteristics of patients with these findings. Methods: This retrospective, single-center study included 742 unique patients aged ≥60 years who were evaluated at Giresun Training and Research Hospital between January 2022 and December 2024. Of these, 454 underwent duodenal biopsy, and 343 underwent celiac disease serological testing; 55 patients underwent both investigations and were therefore included in both test-specific groups. Age, sex, routine hematological and biochemical parameters, tissue transglutaminase antibodies (tTG), endomysial antibodies (EMA), Marsh classification, and histopathological findings were analyzed. All eligible patients were included, and no formal hypothesis testing was performed for the small groups with isolated IgG-class tTG/EMA positivity or histopathological findings potentially compatible with CD. Results: Isolated IgG-class tTG/EMA positivity was detected in 3 of 343 serologically evaluated patients (0.9%; 95% CI, 0.2–2.5%); no patients showed IgA-class tTG or EMA positivity. Histopathological findings potentially compatible with CD were identified in 8 of 454 patients who underwent duodenal biopsy (1.8%; 95% CI, 0.8–3.4%). Of these eight patients, six had nonspecific Marsh type 1 changes, and two had Marsh type 3b changes. Conclusions: Isolated IgG-class tTG/EMA positivity and histopathological findings potentially compatible with CD were identified among older adults undergoing routine clinical evaluation. However, nonspecific Marsh type 1 changes and the hospital-based study design preclude interpretation of these frequencies as confirmed CD prevalence. CD should therefore remain in the differential diagnosis of older adults when compatible clinical, serological, or histopathological findings are present.

1. Introduction

Celiac disease (CD) is defined as an enhanced immunological response to ingested gluten-containing foods derived from wheat, barley, or rye in genetically susceptible individuals [1]. It is a gluten-sensitive enteropathy characterized by villous atrophy, crypt hyperplasia, and increased numbers of intraepithelial lymphocytes. CD is frequently associated with various autoimmune disorders and an increased risk of gastrointestinal malignancy [2]. Although abdominal pain, diarrhea, steatorrhea, bloating, and other nonspecific gastrointestinal symptoms are common, the disease may also present with extraintestinal manifestations such as weight loss, aphthous ulcers, fatigue, arthralgia, arthritis, myalgia, dermatitis herpetiformis, depression, and neurological symptoms; consequently, the diagnosis may initially be missed [1].
CD affects approximately 0.6–1% of the global population [3]. Studies conducted in adults in Türkiye have reported a frequency of approximately 1:140 (0.7%) [4]. Exogenous exposure to gluten, genetic susceptibility, a pro-autoimmune genetic background, early cessation of breastfeeding, sex, viral infections, and tissue injury may contribute to the development of CD [5].
The disease can involve multiple organ systems and has a heterogeneous clinical presentation. Manifestations vary according to age and are generally classified as intestinal or extraintestinal [6]. Historically, CD was considered a disorder that primarily presented in infants and young children with malabsorption and growth failure. Age-related variation in the clinical presentation of CD has been described in both adult and pediatric populations [6,7]. The identification of substantially more asymptomatic than symptomatic cases through population screening has led to the well-known ‘celiac iceberg’ concept [8].
Several serological antibody tests can be used as first-line investigations in patients with suspected CD [9,10,11]. Deamidated gliadin peptide (DGP) antibodies have also been evaluated as screening tests for celiac disease in comparison with tTG [11].
Antigliadin antibodies (AGA) are no longer recommended as initial tests because of their relatively low sensitivity and specificity. EMA testing is characterized by very high specificity but is more expensive. tTG testing likewise demonstrates high sensitivity and specificity while being less costly; therefore, IgA tTG is currently the preferred serological test for the diagnosis and follow-up of CD [9,10,11,12].
Endoscopic abnormalities described in CD include mucosal flattening, scalloping, reduced duodenal folds, and a mosaic pattern. Increased vascularity and, less commonly, mucosal nodularity may also occur, and the mucosa may bleed easily. However, none of these findings are sufficiently sensitive or specific for CD. Histopathological examination of small-bowel biopsy specimens therefore remains an important component of diagnosis [13]. The Marsh criteria are widely used for histopathological assessment, although modifications and revised diagnostic classifications have been proposed [14,15].
Lifelong adherence to a gluten-free diet remains the cornerstone of treatment, while prolonged untreated disease may be associated with complications including osteoporosis and gastrointestinal malignancy [16,17].
Recent evidence continues to demonstrate a substantial global burden of celiac disease. A 2026 systematic review and meta-analysis including 87 studies and 394,274 individuals reported a global seroprevalence of 1.5% and a biopsy-confirmed prevalence of 0.8% [18]. Despite increasing awareness and improved diagnostic strategies, a considerable proportion of patients remain undiagnosed, partly because of the heterogeneous and frequently extraintestinal clinical presentation of the disease [19]. This issue may be particularly relevant in older adults, in whom symptoms can be subtle or atypical, and celiac disease may therefore remain underrecognized [20]. Previous studies have shown that the clinical presentation of celiac disease varies with age and that the disease may be underrecognized in older adults [6,20]. Although celiac disease in older adults has received increasing attention, evidence in this age group remains less extensive than in younger populations, and data from Türkiye specifically focusing on adults aged ≥60 years are limited [4,20]. Accordingly, the present study aimed to evaluate the frequency of isolated IgG-class tTG/EMA positivity and histopathological findings potentially compatible with CD in individuals aged 60 years and older evaluated in routine clinical practice and to describe the available demographic and laboratory characteristics of patients with these findings.

2. Materials and Methods

2.1. Study Design and Population

This retrospective, single-center study included 742 unique patients evaluated at Giresun Training and Research Hospital (GTRH) between January 2022 and December 2024. Among these patients, 454 underwent duodenal biopsy, and 343 underwent celiac disease (CD) serological testing. Fifty-five patients underwent both investigations and were therefore represented in both test-specific groups. The biopsy and serology groups were analyzed separately according to the investigation performed. No duplicate patient records were counted within either test-specific group. The study period refers to the calendar period from which eligible routinely collected clinical records were identified for inclusion in the final retrospective dataset. The study was conducted at Giresun Training and Research Hospital, a single-center hospital in Giresun, Türkiye. The source population consisted of patients aged ≥60 years who were evaluated in routine clinical practice at this hospital and underwent either celiac serological testing or duodenal biopsy during the study period. A defined population-based catchment denominator was not available; therefore, the study population should be considered hospital-based rather than population-based. The reporting of this study was guided by the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) recommendations for observational studies.

2.2. Eligibility and Data Collection

Eligibility was based on age (≥60 years) and the availability of either duodenal biopsy or CD serological testing. Data were obtained retrospectively from routinely collected clinical, laboratory, and pathology records and included age, sex, routine hematological and biochemical parameters, tTG, EMA, Marsh classification, and duodenal histopathology. The laboratory variables were collected as part of the available retrospective dataset, and no prespecified hypothesis was formulated for individual biochemical parameters. In the revised analysis, laboratory findings are presented descriptively, with hemoglobin, MCV, and ferritin highlighted at the case level because of their clinical relevance to anemia and iron deficiency in celiac disease. Records were identified according to the predefined age and testing criteria; repeated records within the same test-specific group were not counted more than once, and unavailable variables were not inferred. Clinical indications, presenting symptoms or diagnostic suspicions, previous CD diagnosis, and adherence to a gluten-free diet were not systematically available and therefore could not be reliably assessed. Accordingly, it was not possible to determine whether duodenal biopsies were obtained specifically because of suspected celiac disease or for other clinical indications, nor could a standardized endoscopy-unit biopsy protocol be reconstructed from the available retrospective records. Anemia was defined as hemoglobin < 13.0 g/dL in men and <12.0 g/dL in women. Because the retrospective dataset contained only eligible records, the numbers initially assessed for eligibility and excluded before dataset construction could not be reliably reconstructed.

2.3. Serological Assessment

Among the 343 patients evaluated serologically, tTG-IgA, tTG-IgG, EMA-IgA, and EMA-IgG were available for all patients. EMA results were available for all 343 patients, including those with negative tTG results; therefore, EMA analysis was not restricted to tTG-positive samples in the study dataset. In the study dataset, isolated IgG-class tTG/EMA positivity was defined as concurrent EMA-IgG and tTG-IgG positivity with negative EMA-IgA and tTG-IgA results. No patients showed isolated EMA or tTG positivity. Total serum IgA levels were not available in the study dataset. Information regarding assay manufacturers, analytical platforms, and laboratory cut-off values could not be reliably reconstructed from the retrospective records available for the 2022–2024 study period.

2.4. Endoscopic and Histopathological Assessment

Among patients who underwent duodenal biopsy, histopathological findings were categorized according to the Marsh classification as reported in the original pathology reports. The use of the Marsh 3b category is consistent with the modified Marsh–Oberhuber classification. Marsh type 1 was defined by an intraepithelial lymphocyte count of ≥25 per 100 enterocytes in the absence of villous atrophy. Two patients were reported as Marsh type 3b in the original pathology reports. Biopsy specimens were not re-evaluated specifically for the present study; histopathological classifications were extracted retrospectively from the original pathology reports. Standardized information regarding the number and exact anatomical location of duodenal biopsy specimens was not available in the retrospective records.

2.5. Statistical Analysis

Statistical analyses were performed using SPSS version 23.0 for Windows (SPSS Inc., Chicago, IL, USA). Continuous variables were summarized descriptively using the median (minimum–maximum), and categorical variables were presented as frequencies and percentages. Because no formal inferential comparisons were performed for the small groups with isolated IgG-class tTG/EMA positivity or histopathological findings potentially compatible with CD in the revised analysis, normality testing was not used to select statistical tests for these comparisons. Given the very small number of patients with isolated IgG-class tTG/EMA positivity (n = 3) or histopathological findings potentially compatible with celiac disease (n = 8), no formal hypothesis testing was performed for comparisons involving these groups. The frequencies of the main serological and histopathological findings were reported with 95% exact binomial confidence intervals. Because of the retrospective design, no a priori sample size calculation was performed, and all eligible patients identified during the study period were included.

3. Results

3.1. Characteristics of the Study Population

A total of 742 unique patients were included in the study. Duodenal biopsy was performed in 454 patients, while 343 patients underwent celiac serological testing. Fifty-five patients underwent both investigations and were therefore represented in both test-specific groups. No patient was counted more than once within the same test-specific group. In the duodenal biopsy group, 263 patients (57.9%) were female, and 191 (42.1%) were male. In the serology group, 205 patients (59.8%) were female, and 138 (40.2%) were male (Table 1).
Table 1. Age and sex distribution of the study population.

3.2. Duodenal Biopsy and Serological Findings

Histopathological findings potentially compatible with CD were identified in 8 of 454 patients (1.8%; 95% CI, 0.8–3.4%) in the duodenal biopsy group. Among these eight patients, five were male, and three were female. Histopathological examination revealed Marsh type 1 changes in six patients and Marsh type 3b changes in two patients. Given the nonspecific nature of Marsh type 1 lesions, the absence of serological data in five of these patients, and negative serology in the remaining patient, the six patients with Marsh type 1 findings could not be considered to have definitively confirmed CD based on histopathology alone. In the serology group, isolated IgG-class tTG/EMA positivity was detected in 3 of 343 patients (0.9%; 95% CI, 0.2–2.5%); no patients showed IgA-class tTG or EMA positivity. Two of these patients were male, and one was female (Table 2). No isolated EMA or tTG positivity was identified. Among the three patients with isolated IgG-class tTG/EMA positivity, two also underwent duodenal biopsy, and both had Marsh 0 histology; no duodenal biopsy record was available in the biopsy dataset for the remaining patient with this serological pattern. Among the six patients with Marsh type 1 changes, one had available celiac serology and was seronegative. Neither of the two patients with Marsh type 3b changes had a corresponding serological record in the study dataset. No additional information regarding serology outside the study dataset, HLA typing, the indication for endoscopy, subsequent celiac disease diagnosis, or response to a gluten-free diet was available in the records used for the present study. Thus, the three patients with isolated IgG-class tTG/EMA positivity and the eight patients with histopathological findings represented 11 distinct individuals.
Table 2. Sex distribution according to biopsy and serological findings.

3.3. Case-Level Laboratory Characteristics

Given the small number of patients with isolated IgG-class tTG/EMA positivity or histopathological findings potentially compatible with celiac disease, laboratory characteristics were summarized descriptively rather than subjected to formal hypothesis testing. Individual-level age, sex, histopathological findings, serological results, hemoglobin, MCV, and ferritin values for the 11 patients are presented in Table 3. Using the sex-specific hemoglobin thresholds defined above, anemia was present in 4 of 8 patients (50.0%) with histopathological findings potentially compatible with CD and in 213 of 446 patients (47.8%) without such findings. Anemia was present in 1 of 3 patients (33.3%) with isolated IgG-class tTG/EMA positivity and in 114 of 340 patients without this serological pattern (33.5%).
Table 3. Individual characteristics of patients with isolated IgG-class tTG/EMA positivity or histopathological findings potentially compatible with celiac disease.

4. Discussion

Although CD was previously considered a rare disease, earlier studies reported worldwide prevalence estimates ranging from approximately 0.3% to 1.2% [21]. Geographic and ethnic variation in celiac disease frequency has also been reported [22,23,24].
Celiac disease in older adults may be particularly challenging to recognize because gastrointestinal symptoms can be less prominent, whereas extraintestinal manifestations such as anemia, osteoporosis, fatigue, and weight loss may predominate [20,25]. Diagnostic delay may therefore be more common in this age group, and alternative causes of enteropathy also become increasingly relevant with advancing age. Previous studies have shown that celiac disease can remain undiagnosed in older populations and that biopsy-proven disease is not negligible in this age group [20,25,26]. In this context, the present findings support maintaining clinical suspicion for celiac disease in selected older adults while emphasizing that serological and histopathological abnormalities must be interpreted together with the broader clinical context.
Studies conducted in adults in Türkiye have reported a celiac disease frequency of approximately 0.7% [4]. In the present hospital-based cohort, isolated IgG-class tTG/EMA positivity was identified in 3 of 343 patients (0.9%), while no patients showed IgA-class tTG or EMA positivity; notably, the two patients with isolated IgG-class positivity who underwent duodenal biopsy both had Marsh 0 histology. In the absence of documented IgA deficiency, the positive predictive value of this isolated IgG-class tTG/EMA pattern for celiac disease is uncertain and appears limited in the present cohort, particularly because both patients who underwent duodenal biopsy had Marsh 0 histology. Histopathological findings potentially compatible with CD were observed in 8 of 454 patients (1.8%). Because six of the eight histopathological cases consisted of nonspecific Marsh type 1 changes, the biopsy-based frequency should not be interpreted as confirmed celiac disease prevalence.
The biopsy and serology groups represented hospital-based populations rather than standardized screening cohorts, and the indications for testing were not systematically available; moreover, the specific clinical indications for obtaining duodenal biopsies could not be reconstructed from the available records. Therefore, differences between the frequencies observed in the two test-specific groups may reflect selection and indication bias and should not be interpreted as evidence of a true difference in celiac disease frequency.
Recent meta-analytic data have reported a global celiac disease seroprevalence of approximately 1.5% and a biopsy-confirmed prevalence of 0.8% [18]. However, direct comparison with the present hospital-based cohort is limited by differences in patient selection, age distribution, and diagnostic methodology.
Over the past two decades, it has become evident that CD can present across a broad clinical spectrum, ranging from severe malabsorption with profound nutritional deficiencies to isolated manifestations such as anemia, accelerated osteoporosis, or osteomalacia. Intestinal symptoms may be less prominent in older patients with CD than in younger individuals [25]. A Finnish study reported a prevalence of biopsy-proven CD of 2.13% among individuals aged 52–74 years [26].
Anemia may be a presenting feature of CD and is common among affected patients [27]. Using sex-specific hemoglobin thresholds, anemia was present in 4 of 8 patients (50.0%) with histopathological findings potentially compatible with CD and in 213 of 446 patients (47.8%) without such findings; among serologically evaluated patients, anemia was present in 1 of 3 patients (33.3%) with isolated IgG-class tTG/EMA positivity and in 114 of 340 patients without this serological pattern (33.5%). Given the very small number of patients with positive findings, these results are presented descriptively and should not be interpreted as evidence of an association between anemia and celiac disease in this cohort.
Our findings support consideration of CD in the differential diagnosis of older adults, particularly when clinical suspicion is present. The main contribution of the present study is therefore not an estimate of population prevalence but a description of serological and histopathological findings encountered among older adults undergoing routine clinical evaluation. The predominance of nonspecific Marsh type 1 changes and the incomplete overlap between serological and histopathological assessment underscore the importance of interpreting these findings together with the clinical context rather than relying on a single abnormal test result. Accordingly, the clinical implication of our findings is to maintain awareness of celiac disease in older adults when compatible clinical, serological, or histopathological findings are present rather than to support routine screening of the general older population.
Among the eight patients with histopathological findings potentially compatible with CD, five (62.5%) were male, and three (37.5%) were female. Histopathological examination revealed Marsh type 1 changes in six patients (75%) and Marsh type 3b changes in two patients (25%). Because Marsh type 1 changes are nonspecific and serological confirmation was unavailable for most of these patients, they should be interpreted cautiously and should not be considered diagnostic of CD on the basis of histopathology alone. In older adults, isolated Marsh type 1 changes have a broad differential diagnosis and may also be associated with conditions such as Helicobacter pylori infection, NSAID or olmesartan exposure, small-intestinal bacterial overgrowth, giardiasis, common variable immunodeficiency, and other non-celiac enteropathies [12,28]. Information regarding these alternative causes was not systematically available in the retrospective dataset and therefore could not be evaluated in the present study. This further limits the specificity of the Marsh type 1 findings for celiac disease. The two patients with Marsh type 3b lesions had no corresponding serological data or additional diagnostic information available in the study records. Therefore, although villous atrophy is more strongly associated with celiac disease than isolated Marsh type 1 changes, alternative non-celiac causes of villous atrophy, including medication-related, infectious, immunodeficiency-related, and other immune-mediated enteropathies, cannot be excluded [12,28].
Current diagnostic guidelines emphasize an integrated diagnostic approach based on serological, histopathological, and clinical findings [12,28]. These guidelines recommend IgA-based tTG testing as the first-line serological approach, with IgG-based testing primarily used in selected settings such as IgA deficiency [12,28]. The 2025 ESsCD guideline conditionally limits the no-biopsy diagnostic approach to selected adults younger than 45 years who meet specific serological criteria; therefore, this pathway is not applicable to the present cohort of patients aged ≥60 years [28]. The 2025 European Society for the Study of Coeliac Disease guidelines recommend standardized duodenal sampling with at least four biopsies from the distal duodenum plus two biopsies from the duodenal bulb [28]. Because standardized information regarding the number and exact anatomical location of biopsy specimens was unavailable in our retrospective dataset, this represents an additional limitation of the present study.

5. Limitations

This study has several limitations. Its retrospective, single-center design and hospital-based study population limit the generalizability of the findings and may have introduced selection bias. In addition, the clinical indications for serological testing and duodenal biopsy, previous celiac disease diagnoses, and adherence to a gluten-free diet were not systematically available in the retrospective records. Therefore, the extent to which these factors influenced patient selection and the observed frequencies could not be determined. The biopsy and serology groups were partially overlapping, with 55 patients undergoing both investigations; however, the groups were assessed using different diagnostic approaches and therefore could not be directly compared as equivalent diagnostic cohorts. In addition, most histopathologically compatible cases showed nonspecific Marsh type 1 changes, with serological data unavailable for most of these patients and negative serology in the only patient with available testing. The small number of patients with isolated IgG-class tTG/EMA positivity or histopathological findings potentially compatible with CD limited the precision and interpretability of these findings; therefore, they were interpreted descriptively without formal subgroup hypothesis testing. Because all three patients with isolated IgG-class tTG/EMA positivity had negative IgA-class assays and total serum IgA was unavailable, the diagnostic significance of this serological pattern could not be fully established. Finally, incomplete information regarding serological assay characteristics and biopsy sampling may have affected diagnostic assessment.

6. Conclusions

Celiac disease should be considered in the differential diagnosis of older adults, particularly in the presence of compatible clinical, serological, or histopathological findings. In this hospital-based cohort, isolated IgG-class tTG/EMA positivity was identified in 0.9% of serologically evaluated patients, with no IgA-class tTG or EMA positivity observed, while histopathological findings potentially compatible with CD were observed in 1.8% of patients who underwent duodenal biopsy. Because most biopsy-compatible findings consisted of nonspecific Marsh type 1 changes and the study was not population-based, these frequencies should not be interpreted as confirmed CD prevalence in the older population. Greater clinical awareness may help reduce missed or delayed diagnoses in this age group.

Author Contributions

Conceptualization, A.S.Y. and A.C.D.; methodology, A.S.Y., A.C.D. and G.A.; investigation, A.S.Y.; data curation, A.S.Y.; writing—original draft preparation, A.S.Y.; writing—review and editing, A.C.D. and G.A.; supervision, A.C.D. and G.A. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki. Ethical approval for this retrospective study was granted by the Ethics Committee of Giresun Training and Research Hospital. The application entitled “Retrospective Serological and Endoscopic Evaluation of the Prevalence of Celiac Disease in the Population Aged Over 60 Years at Giresun Training and Research Hospital” (Application No. BAEK-27) was reviewed at the meeting held on 24 April 2024 and was unanimously approved for compliance with ethical principles and rules (Decision No. 24.04.2024/03).

Data Availability Statement

The datasets generated and/or analyzed during the current study are not publicly available because of institutional regulations and patient confidentiality but are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
AGAantigliadin antibodies
CDceliac disease
CIconfidence interval
DGPdeamidated gliadin peptide
EMAendomysial antibodies
ESsCDEuropean Society for the Study of Coeliac Disease
GTRHGiresun Training and Research Hospital
HLAhuman leukocyte antigen
Hbhemoglobin
IgAimmunoglobulin A
IgGimmunoglobulin G
MCVmean corpuscular volume
NSAIDnonsteroidal anti-inflammatory drug
STROBEStrengthening the Reporting of Observational Studies in Epidemiology
tTGtissue transglutaminase antibodies

References

  1. Hopper, A.D.; Hadjivassiliou, M.; Butt, S.; Sanders, D.S. Adult coeliac disease. BMJ 2007, 335, 558–562. [Google Scholar] [CrossRef] [Scilit]
  2. Periolo, N.; Cherñavsky, A.C. Coeliac disease. Autoimmun. Rev. 2006, 5, 202–208. [Google Scholar] [CrossRef] [Scilit]
  3. Biagi, F.; Klersy, C.; Balduzzi, D.; Corazza, G.R. Are we not over-estimating the prevalence of coeliac disease in the general population? Ann. Med. 2010, 42, 557–561. [Google Scholar] [CrossRef] [Scilit]
  4. Gursoy, S.; Guven, K.; Simsek, T.; Yurci, A.; Torun, E.; Koc, N.; Patiroglu, T.E.; Ozbakir, O.; Yucesoy, M. The prevalence of unrecognized adult celiac disease in Central Anatolia. J. Clin. Gastroenterol. 2005, 39, 508–511. [Google Scholar] [CrossRef] [Scilit]
  5. Stepniak, D.; Koning, F. Celiac disease--sandwiched between innate and adaptive immunity. Hum. Immunol. 2006, 67, 460–468. [Google Scholar] [CrossRef] [Scilit]
  6. Vivas, S.; Vaquero, L.; Rodríguez-Martín, L.; Caminero, A. Age-related differences in celiac disease: Specific characteristics of adult presentation. World J. Gastrointest. Pharmacol. Ther. 2015, 6, 207–212. [Google Scholar] [CrossRef] [Scilit]
  7. Khatib, M.; Baker, R.D.; Ly, E.K.; Kozielski, R.; Baker, S.S. Presenting Pattern of Pediatric Celiac Disease. J. Pediatr. Gastroenterol. Nutr. 2016, 62, 60–63. [Google Scholar] [CrossRef] [Scilit]
  8. Mäki, M.; Collin, P. Coeliac disease. Lancet 1997, 349, 1755–1759. [Google Scholar] [CrossRef] [Scilit]
  9. Leffler, D.A.; Schuppan, D. Update on serologic testing in celiac disease. Am. J. Gastroenterol. 2010, 105, 2520–2524. [Google Scholar] [CrossRef] [Scilit]
  10. Reddick, B.K.; Crowell, K.; Fu, B. Clinical inquiries: What blood tests help diagnose celiac disease? J. Fam. Pract. 2006, 55, 1088–1093. [Google Scholar]
  11. Lewis, N.R.; Scott, B.B. Meta-analysis: Deamidated gliadin peptide antibody and tissue transglutaminase antibody compared as screening tests for coeliac disease. Aliment. Pharmacol. Ther. 2010, 31, 73–81. [Google Scholar] [CrossRef] [Scilit]
  12. Rubio-Tapia, A.; Hill, I.D.; Semrad, C.; Kelly, C.P.; Greer, K.B.; Limketkai, B.N.; Lebwohl, B. American College of Gastroenterology guidelines update: Diagnosis and management of celiac disease. Am. J. Gastroenterol. 2023, 118, 59–76. [Google Scholar] [CrossRef] [Scilit]
  13. Green, P.H.; Murray, J.A. Routine duodenal biopsies to exclude celiac disease? Gastrointest. Endosc. 2003, 58, 92–95. [Google Scholar] [CrossRef] [Scilit]
  14. Villanacci, V.; Ceppa, P.; Tavani, E.; Vindigni, C.; Volta, U.; Gruppo Italiano Patologi Apparato Digerente (GIPAD); Società Italiana di Anatomia Patologica e Citopatologia Diagnostica/International Academy of Pathology, Italian division (SIAPEC/IAP). Coeliac disease: The histology report. Dig. Liver Dis. 2011, 43, S385–S395. [Google Scholar] [CrossRef] [Scilit]
  15. Oberhuber, G.; Granditsch, G.; Vogelsang, H. The histopathology of coeliac disease: Time for a standardized report scheme for pathologists. Eur. J. Gastroenterol. Hepatol. 1999, 11, 1185–1194. [Google Scholar] [CrossRef] [Scilit]
  16. Farrell, R.J.; Kelly, C.P. Celiac sprue. N. Engl. J. Med. 2002, 346, 180–188. [Google Scholar] [CrossRef] [Scilit]
  17. Catassi, C.; Bearzi, I.; Holmes, G.K. Association of celiac disease and intestinal lymphomas and other cancers. Gastroenterology 2005, 128, S79–S86. [Google Scholar] [CrossRef] [Scilit]
  18. Karimzadhagh, S.; Abbaspour, E.; Shamsi, P.; Shahriarinamin, M.; Shiha, M.G.; Pinto-Sanchez, M.I.; Yuan, Y.; Koulaouzidis, A.; Agardh, D.; Catassi, C.; et al. Global prevalence of celiac disease and clinical characteristics in the general population: A systematic review and meta-analysis. Gastroenterology 2026, in press. [Google Scholar] [CrossRef] [Scilit]
  19. Gatti, S.; Rubio-Tapia, A.; Makharia, G.; Catassi, C. Patient and community health global burden in a world with more celiac disease. Gastroenterology 2024, 167, 23–33. [Google Scholar] [CrossRef] [Scilit]
  20. Ching, C.K.; Lebwohl, B. Celiac disease in the elderly. Curr. Treat. Options Gastroenterol. 2022, 20, 238–249. [Google Scholar] [CrossRef] [Scilit]
  21. Fasano, A.; Catassi, C. Current approaches to diagnosis and treatment of celiac disease: An evolving spectrum. Gastroenterology 2001, 120, 636–651. [Google Scholar] [CrossRef] [Scilit]
  22. Wang, M.; Kong, W.J.; Feng, Y.; Lu, J.J.; Hui, W.J.; Liu, W.D.; Li, Z.Q.; Shi, T.; Cui, M.; Sun, Z.Z.; et al. Epidemiological, clinical, and histological presentation of celiac disease in Northwest China. World J. Gastroenterol. 2022, 28, 1272–1283. [Google Scholar] [CrossRef] [Scilit]
  23. Zhou, C.; Gao, F.; Gao, J.; Yuan, J.; Lu, J.; Sun, Z.; Xu, M.; Engel, J.; Hui, W.; Gilissen, L.; et al. Prevalence of coeliac disease in Northwest China: Heterogeneity across Northern Silk road ethnic populations. Aliment. Pharmacol. Ther. 2020, 51, 1116–1129. [Google Scholar] [CrossRef] [Scilit]
  24. Poddighe, D.; Turganbekova, A.; Baymukasheva, D.; Saduakas, Z.; Zhanzakova, Z.; Abdrakhmanova, S. Genetic predisposition to celiac disease in Kazakhstan: Potential impact on the clinical practice in Central Asia. PLoS ONE 2020, 15, e0226546. [Google Scholar] [CrossRef] [Scilit]
  25. Freeman, H.J. Adult celiac disease in the elderly. World J. Gastroenterol. 2008, 14, 6911–6914. [Google Scholar] [CrossRef] [Scilit]
  26. Vilppula, A.; Collin, P.; Mäki, M.; Valve, R.; Luostarinen, M.; Krekelä, I.; Patrikainen, H.; Kaukinen, K.; Luostarinen, L. Undetected coeliac disease in the elderly: A biopsy-proven population-based study. Dig. Liver Dis. 2008, 40, 809–813. [Google Scholar] [CrossRef] [Scilit]
  27. Halfdanarson, T.R.; Litzow, M.R.; Murray, J.A. Hematologic manifestations of celiac disease. Blood 2007, 109, 412–421. [Google Scholar] [CrossRef] [Scilit]
  28. Al-Toma, A.; Zingone, F.; Branchi, F.; Schiepatti, A.; Malamut, G.; Canova, C.; Rosato, I.; Ocagli, H.; Trott, N.; Elli, L.; et al. European Society for the Study of Coeliac Disease 2025 updated guidelines on the diagnosis and management of coeliac disease in adults. Part 1: Diagnostic approach. United Eur. Gastroenterol. J. 2025, 13, 1855–1886. [Google Scholar] [CrossRef] [Scilit]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Article metric data becomes available approximately 24 hours after publication online.